ALS biomarker study aims to unlock disease clues
NCT ID NCT07260981
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at 60 people — 30 with ALS and 30 healthy volunteers — to measure immune system and nerve damage markers in their blood and spinal fluid. The goal was to better understand the role of a specific immune pathway (IFN-alpha) in ALS. By linking these markers to patient symptoms, researchers hope to find better ways to diagnose and track the disease, and to identify new targets for future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could help identify biological markers that improve diagnosis or track ALS progression, and may support future development of treatments targeting the immune system.
What could go wrong
This is an observational biomarker study, not a treatment trial. It is small (60 participants) and completed, so it will not directly lead to a new therapy. Results may not apply to all ALS patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS (AMYOTROPHIC LATERAL SCLEROSIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Jaco Robotic Arm for Tetraplegia Home Use (NCT07680361)
- T-Regulatory Cell Therapy for ALS Trial (NCT03241784)
- NTF001 Gene Therapy for ALS Safety Study (NCT07618585)
- NeuroEXPLORER PET/CT vs Standard PET/CT (NCT07595666)
- Psilocybin for Depression in COPD, ALS, MS, APD NCT06782724
- Probiotics for ALS-FTD: NCT06051123
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pioneer Life Sciences Cherrywood
Dublin, Ireland